Information Provided By: 
Fly News Breaks for March 17, 2016
JAZZ
Mar 17, 2016 | 07:25 EDT
JPMorgan analyst Jessica Fye says she's "even more positive" on shares of Jazz Pharmaceuticals after meeting with the company's CFO Matt Young. The analyst finds it increasingly likely that Jazz will complete one or more transactions this year given its "very healthy" balance sheet. Further, potential clarity on Xyrem durability and pipeline progress position the stock well for this year, Fye tells investors in a research note. She reiterates an Overweight rating on Jazz with a $200 price target.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
